Kissei Pharmaceutical Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Mutsuo Kanzawa

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	41.8yrs
CEO ownership	3.5%
Management average tenure	3.8yrs
Board average tenure	8.8yrs

Recent management updates

Recent updates

CEO

Mutsuo Kanzawa (74 yo)

41.8yrs

Tenure

Mr. Mutsuo Kanzawa is Chief Executive Officer of Kissei Pharmaceutical Co. Ltd and served as its President since June 1992. Mr. Kanzawa has been the Chairman of Kissei Pharmaceutical Co. Ltd. since June 20...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Mutsuo Kanzawa	Chairman & CEO	no data	no data	3.49% ¥ 35.0m
Yasuo Takehana	President	1.8yrs	no data	0.034% ¥ 340.7k
Takahide Kitahara	GM of Financial Management Department	11.8yrs	no data	0.018% ¥ 181.7k
Yoshio Furihata	Senior Advisor & Director	13.8yrs	no data	0.027% ¥ 272.6k
Keiji Fukushima	Executive VP & Director	11.8yrs	no data	0.023% ¥ 227.1k
Tetsu Takayama	Executive MD & Director	3.8yrs	no data	0.032% ¥ 318.0k
Hiroshi Noake	GM of Pharmaceutical Sales Headquarters & Director	1.8yrs	no data	0.0023% ¥ 22.7k
Keiji Miyazawa	GM of Research Division & Director	1.8yrs	no data	0.0023% ¥ 22.7k

3.8yrs

Average Tenure

61.5yo

Average Age

Experienced Management: KSPH.F's management team is considered experienced (3.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Mutsuo Kanzawa	Chairman & CEO	41.8yrs	no data	3.49% ¥ 35.0m
Yasuo Takehana	President	12.3yrs	no data	0.034% ¥ 340.7k
Takahide Kitahara	GM of Financial Management Department	5.8yrs	no data	0.018% ¥ 181.7k
Yoshio Furihata	Senior Advisor & Director	15.8yrs	no data	0.027% ¥ 272.6k
Keiji Fukushima	Executive VP & Director	11.8yrs	no data	0.023% ¥ 227.1k
Tetsu Takayama	Executive MD & Director	9.8yrs	no data	0.032% ¥ 318.0k
Hiroshi Noake	GM of Pharmaceutical Sales Headquarters & Director	1.8yrs	no data	0.0023% ¥ 22.7k
Keiji Miyazawa	GM of Research Division & Director	1.8yrs	no data	0.0023% ¥ 22.7k
Shigetaka Shimizu	Independent Outside Director	9.8yrs	no data	0.0068% ¥ 68.2k
Sayuri Uchikawa	Independent Outside Director	3.8yrs	no data	0.0023% ¥ 22.7k
Minoru Nomura	Independent Outside Director	7.8yrs	no data	0.0091% ¥ 90.9k
Yoshinori Otsuki	Independent Outside Director	1.8yrs	no data	no data

8.8yrs

Average Tenure

63yo

Average Age

Experienced Board: KSPH.F's board of directors are considered experienced (8.8 years average tenure).

Kissei Pharmaceutical Management

Management criteria checks 2/4

Key information

Recent management updates

Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 22, 2023

Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2022

Recent updates

Kissei Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 07, 2024

Kissei Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 2024

Kissei Pharmaceutical Co., Ltd. and Maruishi Pharmaceutical Co., Ltd. Announces KORSUVA®? IV Injection Syringe for Dialysis 17.5ug, 25.0ug to Launch in Japan for Treatment of Pruritus in Patients Undergoing Hemodialysis

Kissei Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Jan 30, 2024

Kissei Pharmaceutical Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ending September 30, 2023

Kissei Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 07, 2023

Kissei Pharmaceutical Co., Ltd. Announces Withdrawal of Application for Marketing Approval for Rovatirelin for the Treatment of Spinocerebellar Degeneration in Japan

Kissei Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 22, 2023

Kissei Pharmaceutical Co., Ltd. (TSE:4547) announces an Equity Buyback for 2,000,000 shares, representing 4.34% for ¥6,000 million.

Kissei Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Kissei Pharmaceutical Co., Ltd. Receives Marketing Authorization Approval in Japan for TAVALISSE Tab. 100Mg and 150Mg, an Oral Spleen Tyrosine Kinase Inhibitor

Kissei Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023

Kissei Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter and Dividend Guidance for Year Ending of March 31, 2023, Payable Date on December 2, 2022

Kissei Pharmaceutical Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ending September 30, 2022

Kissei Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Nov 08, 2022

Kissei Pharmaceutical Co., Ltd. Provides Earning Guidance for the First Half Ending September 30, 2022 and Full Year Ending March 31, 2023

Kissei Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 01, 2022

Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2022

Kissei Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 10, 2022

Kissei Pharmaceutical Co., Ltd. Releases Positive Topline Results from Its Phase 3 Clinical Trial in Japan

Kissei Pharmaceutical Co., Ltd. announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan

Kissei Pharmaceutical Co., Ltd. to Report Fiscal Year 2021 Results on May 11, 2021

Kissei Pharmaceutical Co., Ltd. to Report Q3, 2021 Results on Feb 01, 2021

Kissei Pharmaceutical Co., Ltd. to Report Q2, 2021 Results on Nov 15, 2020

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age